S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
Log in
NASDAQ:AUPH

Aurinia Pharmaceuticals Stock Forecast, Price & News

$14.66
0.00 (0.00 %)
(As of 12/2/2020 04:48 PM ET)
Add
Compare
Today's Range
$14.25
Now: $14.66
$14.70
50-Day Range
$12.96
MA: $14.63
$16.05
52-Week Range
$7.32
Now: $14.66
$21.93
Volume671,275 shs
Average Volume1.41 million shs
Market Capitalization$1.85 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.1
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.
Aurinia Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.58 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AUPH
CUSIPN/A
Phone250-708-4272
Employees62

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$320,000.00
Book Value$3.15 per share

Profitability

Net Income$-123,850,000.00
Net Margins-173,992.23%

Miscellaneous

Market Cap$1.85 billion
Next Earnings Date3/4/2021 (Estimated)
OptionableOptionable
$14.66
0.00 (0.00 %)
(As of 12/2/2020 04:48 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AUPH News and Ratings via Email

Sign-up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions

How has Aurinia Pharmaceuticals' stock been impacted by COVID-19?

Aurinia Pharmaceuticals' stock was trading at $14.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AUPH stock has increased by 4.3% and is now trading at $14.70.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aurinia Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aurinia Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Aurinia Pharmaceuticals?

Wall Street analysts have given Aurinia Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aurinia Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aurinia Pharmaceuticals' next earnings date?

Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Aurinia Pharmaceuticals
.

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) issued its quarterly earnings results on Sunday, November, 15th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.05. Aurinia Pharmaceuticals had a negative net margin of 173,992.23% and a negative return on equity of 36.98%.
View Aurinia Pharmaceuticals' earnings history
.

What price target have analysts set for AUPH?

8 brokers have issued 1 year target prices for Aurinia Pharmaceuticals' stock. Their forecasts range from $20.00 to $28.00. On average, they expect Aurinia Pharmaceuticals' share price to reach $23.71 in the next twelve months. This suggests a possible upside of 61.3% from the stock's current price.
View analysts' price targets for Aurinia Pharmaceuticals
.

Are investors shorting Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 5,120,000 shares, an increase of 20.5% from the October 31st total of 4,250,000 shares. Based on an average daily volume of 1,040,000 shares, the short-interest ratio is currently 4.9 days. Currently, 4.7% of the shares of the company are short sold.
View Aurinia Pharmaceuticals' Short Interest
.

Who are some of Aurinia Pharmaceuticals' key competitors?

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the following people:
  • Mr. Peter S. Greenleaf M.B.A., Pres, CEO & Director (Age 50, Pay $1.06M)
  • Dr. Erik R. Eglite J.D., M.B.A., D.P.M., Sr. VP, Gen. Counsel & Chief Corp. Compliance Officer (Age 55, Pay $527.42k)
  • Dr. Neil Solomons M.D., Chief Medical Officer
  • Mr. Matthew Maxwell Donley M.B.A., Exec. VP of Internal Operations & Strategy (Age 51, Pay $544.83k)
  • Mr. Michael R. Martin, Co-Founder & COO
  • Mr. Joseph M. Miller CPA, Chief Financial Officer (Age 46)
  • Dr. Glenn Schulman, Sr. VP of Corp. Communications & Investor Relations
  • Dr. Robert B. Huizinga M.Sc., Ph.D., RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
  • Mr. Chris Hays, VP of Marketing
  • Mr. Fran Lynch, VP of Sales

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Great Point Partners LLC (1.97%), Point72 Asset Management L.P. (1.85%), Connor Clark & Lunn Investment Management Ltd. (1.28%), BlackRock Inc. (0.97%), TD Asset Management Inc. (0.37%) and Lord Abbett & CO. LLC (0.36%).

Which major investors are selling Aurinia Pharmaceuticals stock?

AUPH stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Assenagon Asset Management S.A., J. Goldman & Co LP, Victory Capital Management Inc., Allianz Asset Management GmbH, Toronto Dominion Bank, and HighMark Wealth Management LLC.

Which major investors are buying Aurinia Pharmaceuticals stock?

AUPH stock was acquired by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Ardsley Advisory Partners LP, Kestra Private Wealth Services LLC, Wells Fargo & Company MN, Connor Clark & Lunn Investment Management Ltd., Lord Abbett & CO. LLC, International Biotechnology Trust PLC, and Federated Hermes Inc..

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUPH stock can currently be purchased for approximately $14.70.

How big of a company is Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals has a market capitalization of $1.86 billion and generates $320,000.00 in revenue each year. The biotechnology company earns $-123,850,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Aurinia Pharmaceuticals employs 62 workers across the globe.

What is Aurinia Pharmaceuticals' official website?

The official website for Aurinia Pharmaceuticals is www.auriniapharma.com.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-708-4272 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.